Quantity of Melatonin and CBD in Melatonin Gummies Sold in the US
JAMA · 25.04.2023 · 329 (16) · 1401
DOI: 10.1001/jama.2023.2296 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, erschienen am 25.04.2023. Verfasst von Pieter A Cohen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Cambridge Health Alliance, Somerville, Massachusetts. Hauptthemen laut MEDLINE: Cannabidiol, Cannabis, Melatonin. Die Arbeit wurde bisher 77-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
This study assesses the actual measured quantities of melatonin and cannabidiol (CBD) in products marketed and sold in the US as melatonin gummies compared with the quantities declared on their labels.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Cambridge Health Alliance, Somerville, Massachusetts.
- University of Mississippi, University.
Zitieren
APA
Cohen, P. A., Avula, B., Wang, Y. H., Katragunta, K., & Khan, I. (2023). Quantity of Melatonin and CBD in Melatonin Gummies Sold in the US. JAMA, 329(16), 1401. https://doi.org/10.1001/jama.2023.2296
Vancouver
Cohen PA, Avula B, Wang YH, Katragunta K, Khan I. Quantity of Melatonin and CBD in Melatonin Gummies Sold in the US. JAMA. 2023;329(16):1401. doi:10.1001/jama.2023.2296
BibTeX
@article{Cohen2023,
author = {Cohen, Pieter A and Avula, Bharathi and Wang, Yan-Hong and Katragunta, Kumar and Khan, Ikhlas},
title = {Quantity of Melatonin and CBD in Melatonin Gummies Sold in the US},
journal = {JAMA},
year = {2023},
volume = {329},
number = {16},
pages = {1401},
doi = {10.1001/jama.2023.2296}
}
EUVIMED